Browse drugs

…en of nausea and vomiting was reported in patients treated with ipilimumab. 55From patient selection to TIL expansion: a comprehensive ove…

…index of IL-2 by maintaining the superior potency attributed to Aldesleukin treatment without compromising on the improved safety (as measu…

…n conjugated by non-releasable PEG. CD8a + T cells treated with IL-2 mutein conjugated by releasable PEG showed higher CTL activity …

…–800.Rohaan MW, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 2022;387:2113–2125.Zacha…

…neration. After successful TIL production, lymphodepletion with cyclophosphamide (60mg/kg/day IV on days -7 and -6) and fludarabine (25mg/m2 IV …

… ERK4 signaling in NK cells expanded in the presence of IL-2 or IL-15, which can enhance NK cell cytotoxicity.1 4 Here, studies by ou…

… vitro with different doses of cytokines, including IL-2, IL-7, IL-15. IL-2 stimulated human NK cells were co-cultured with human HCC…

…ransformed B lymphoblastoid cell lines (LCL) in the presence of IL-2 leads to extensive NK cell proliferation. Leveraging this insig…

…transfer of autologous T cells from tumor fragments cultured in IL-2 has been successful in treating melanomas and select epithelial…

…cancers. Primary expansion of TIL from tumors was obtained with IL-2, followed by a standard bulk rapid expansion protocol (bulkREP)…

…ective of Phase 1 is to evaluate the safety and tolerability of KSQ-004EX. In Phase 2, patients will be enrolled in indication-specific c…

…nt on the same cell.Conclusions Together, our data suggest that Daiad-2/15 could potentiate the systemic delivery of a highly potent immun…